Van Strum & Towne Inc. lowered its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 0.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,767 shares of the medical research company’s stock after selling 285 shares during the period. Amgen comprises 5.7% of Van Strum & Towne Inc.’s portfolio, making the stock its 4th largest holding. Van Strum & Towne Inc.’s holdings in Amgen were worth $8,200,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in AMGN. Pure Financial Advisors Inc. raised its holdings in Amgen by 2.8% in the second quarter. Pure Financial Advisors Inc. now owns 1,469 shares of the medical research company’s stock valued at $346,000 after acquiring an additional 40 shares in the last quarter. Center for Financial Planning Inc. increased its holdings in shares of Amgen by 5.7% in the 1st quarter. Center for Financial Planning Inc. now owns 793 shares of the medical research company’s stock worth $161,000 after acquiring an additional 43 shares during the period. Investors Financial Group LLC increased its holdings in shares of Amgen by 1.7% in the 1st quarter. Investors Financial Group LLC now owns 2,752 shares of the medical research company’s stock worth $558,000 after acquiring an additional 47 shares during the period. STA Wealth Management LLC increased its holdings in shares of Amgen by 3.8% in the 1st quarter. STA Wealth Management LLC now owns 1,298 shares of the medical research company’s stock worth $263,000 after acquiring an additional 47 shares during the period. Finally, Wealth Architects LLC increased its holdings in shares of Amgen by 2.2% in the 1st quarter. Wealth Architects LLC now owns 2,200 shares of the medical research company’s stock worth $446,000 after acquiring an additional 47 shares during the period. Institutional investors own 75.73% of the company’s stock.

In other news, Director Ronald D. Sugar sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $228.54, for a total transaction of $228,540.00. Following the completion of the transaction, the director now directly owns 16,576 shares in the company, valued at $3,788,279.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $237.31, for a total value of $100,856.75. Following the transaction, the director now owns 5,834 shares of the company’s stock, valued at $1,384,466.54. The disclosure for this sale can be found here. Insiders sold 3,425 shares of company stock valued at $792,017 over the last quarter. Corporate insiders own 0.36% of the company’s stock.

NASDAQ:AMGN traded up $3.05 during trading hours on Tuesday, hitting $253.09. The company’s stock had a trading volume of 2,343,790 shares, compared to its average volume of 3,024,536. The stock has a fifty day simple moving average of $234.07 and a 200-day simple moving average of $226.11. The company has a market capitalization of $146.50 billion, a P/E ratio of 19.53, a PEG ratio of 2.13 and a beta of 0.94. The company has a debt-to-equity ratio of 3.16, a current ratio of 1.59 and a quick ratio of 1.28. Amgen, Inc. has a twelve month low of $173.12 and a twelve month high of $264.97.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.17 earnings per share for the quarter, beating the consensus estimate of $3.70 by $0.47. The business had revenue of $6.16 billion for the quarter, compared to analyst estimates of $6.01 billion. Amgen had a return on equity of 90.75% and a net margin of 32.03%. Amgen’s revenue was up 10.9% compared to the same quarter last year. During the same period last year, the firm posted $3.56 earnings per share. On average, equities analysts predict that Amgen, Inc. will post 15.56 EPS for the current fiscal year.

A number of analysts recently weighed in on the stock. Raymond James raised shares of Amgen from a “market perform” rating to an “outperform” rating and set a $255.00 price objective on the stock in a report on Sunday, March 29th. BMO Capital Markets increased their target price on shares of Amgen from $274.00 to $291.00 and gave the company an “outperform” rating in a research report on Friday, May 1st. BidaskClub upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. Morgan Stanley increased their target price on shares of Amgen from $267.00 to $280.00 and gave the company an “overweight” rating in a research report on Friday, May 1st. Finally, Mizuho reiterated a “hold” rating and issued a $215.00 target price on shares of Amgen in a research report on Thursday, April 30th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eighteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $245.85.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Further Reading: Fundamental Analysis and Individual Investors

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.